Bionano Genomics Inc. (BNGO)
0.21
-0.01 (-5.79%)
At close: Jan 14, 2025, 3:59 PM
0.20
-0.58%
Pre-market Jan 15, 2025, 06:32 AM EST
undefined% (undefined)
| Bid | 0.2 |
| Market Cap | 28.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -0.09 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.21 |
| Volume | 8,727,381 |
| Avg. Volume (20D) | 7,086,663 |
| Open | 0.22 |
| Previous Close | 0.22 |
| Day's Range | 0.20 - 0.26 |
| 52-Week Range | 0.19 - 1.40 |
| Beta | undefined |
About BNGO
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents ...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Aug 21, 2018
Employees 344
Stock Exchange NASDAQ
Ticker Symbol BNGO
Website https://www.bionanogenomics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for BNGO stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 387.09% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Bionano Genomics Inc. is scheduled to release its earnings on Mar 4, 2025,
during market hours.
Analysts project revenue of $6.30M, reflecting a -41.24% YoY shrinking and earnings per share of -0.14, making a -85.42% decrease YoY.
Analysts project revenue of $6.30M, reflecting a -41.24% YoY shrinking and earnings per share of -0.14, making a -85.42% decrease YoY.
2 months ago ·
Source
-7.58%
Bionano Genomics shares are trading lower after th...
Unlock content with
Pro Subscription
2 months ago ·
Source
-14.49%
Bionano Genomics shares are trading lower after the company announced a $3 million registered direct offering.
